On Dec. 29, 2007, President George W. Bush signed the multi-faceted Medicare, Medicaid, and SCHIP Extension Act of 2007. Section 111 of the bill, titled, Medicare Secondary Payor (MSP), mandated that effective Jan. 1, 2009, all Group Health Plans (GHP) or any related entity (i.e. insurer or third party administrator) serving on behalf of the GHP will be responsible for identifying and submitting "situations where the group health plan is or has been a primary plan to the program," according to Medicare.
On Dec. 29, 2007, President George W. Bush signed the multi-faceted Medicare, Medicaid, and SCHIP Extension Act of 2007. Within this bill, Section 111 titled Medicare Secondary Payor (MSP) mandated that effective Jan. 1, 2009, all Group Health Plans (GHP) or any related entity (i.e. insurer or third party administrator) serving on behalf of the GHP will be responsible for identifying and submitting "situations where the group health plan is or has been a primary plan to the program," according to Medicare.
Following are key bill highlights:
This change will significantly impact health plans financially and operationally. Prior to enactment of this law, health plans were only required to submit a notice to Medicare when the health plan identified a situation where Medicare mistakenly paid primary (411.25 notice). The notice requirement did not contain a specific penalty for noncompliance and did not require a health plan to submit to HHS a report that identified all Medicare secondary members. The result of these changes is estimated to shift $100 million to $200 million annually from Medicare to private health plans. Additionally, HHS has the ability to levy large fines to health plans that do not identify and report members who are primary to Medicare.
Impact on health plans
Identification and order of benefit determination
Health plans need to have adequate processes and internal controls to identify Medicare eligible members and make the appropriate benefit determination. The new law would allow CMS to penalize health plans $1,000 per member per day in those situations for not properly reporting Medicare secondary members to CMS. To mitigate this risk, most plans should consider a comprehensive revamping of the processes they use to identify each and every Medicare eligible member within their plan (particularly Medicare eligibles under age 65) and increase the diligence and timeliness of order of benefits determinations.
Systems modification
With new information received on a daily basis, dual eligible members may be added on a daily basis and members' primary determinations may change as quickly. In addition to the new information, there may be gaps in the COB information required to make the necessary primary determinations. Plans will have to ensure all information is uploaded into the various systems (membership, claims, etc.) and the necessary outputs are achieved.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512